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Background: Since available studies have provided conflicting results, this study investigated respiratory muscle function and its relationship with
exercise capacity, degree of dyspnoea and leg discomfort, and quality of life in patients with Cystic Fibrosis (CF).
Methods: Using a cross-sectional design, 27 clinically stable adolescent and adult patients (f/m: 14/13, age: 26±7 years) were included. Data of
respiratory muscle strength (Pimax and Pemax), lung function (spirometry), peripheral muscle strength (peak isometric quadriceps and hand-grip
strength), symptom-limited exercise capacity (modified shuttle test, MST), post-exercise dyspnoea and leg discomfort (Borg scores), and quality
of life (CFQ-14+, MRC) were obtained for further analysis.
Results: Pimax of the total patient group was significantly higher than reference values (Pimax=124±32% predicted), and correlated positively
with the walk/run distance of the MST (rs=0.59, p=0.00). Female patients showed more dyspnoea and a more impaired lung function than male
patients. However, Pimax and Pemax (% predicted) showed a tendency to be higher in female than in male patients.
Conclusion: Increased work of breathing will have a conditioning effect on the respiratory muscles, suggesting that training-related inspiratory
muscle strength can play a positive role in the limited exercise capacity of CF patients.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Exercise capacity; Mouth pressure; Dynamometry; CFQ-14+; Dyspnoea scale1. Introduction
Available studies of respiratory muscle strength in patients
with Cystic Fibrosis (CF) have provided conflicting results,
showing either decreased, normal or supernormal values of
respiratory muscle strength [1–4]. Hyperinflation and malnutri-
tion seem to be the main factors leading to respiratory muscle
weakness [5]. In contrast, chronic cough and increased work of
breathing probably leads to functional compensation with a
preserved or increased respiratory muscle strength [1]. It is
difficult to interpret these studies because of different⁎ Corresponding author. Tel.: +31 887553396; fax: +31 887555450.
E-mail address: w.r.devries@umcutrecht.nl (W.R. de Vries).
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doi:10.1016/j.jcf.2008.07.006characteristics of the patients included, such as age, nutritional
status and the degree of respiratory dysfunction. In addition
different methods and types of measuring respiratory muscle
strength were used [1–4].
It has been suggested that reduced respiratory muscle
strength in CF patients can play a role in respiratory muscle
fatigue and thereby contributing to dyspnoea and ventilatory
failure [5]. Respiratory muscle fatigue may be a consequence of
an imbalance between workload on, and work capacity of the
respiratory muscles. The workload will be increased as a result
of airflow obstructions due to inflammatory processes which
lead to a high airway resistance. [5] Compared to healthy
conditions the work capacity of the respiratory muscles is
reduced because of a diminished power and efficiency of the
respiratory muscles as a result of malnutrition and/or hyperin-
flation[6]. In addition, no direct relationship was found betweend by Elsevier B.V. All rights reserved.
32 M.A. Dunnink et al. / Journal of Cystic Fibrosis 8 (2009) 31–36respiratory muscle weakness and the development of hypox-
emia and hypercapnia during sleep and/or exercise in CF [7]. In
contrast, it is well known that in COPD patients muscle
weakness leads to hypercapnia and oxygen desaturation in
blood during sleep, as well as socio-economical effects, such as
increased medical consumption and decreased survival [8].
Currently a large variation of opinions exists on respiratory
muscle strength in CF patients, and there is insufficient
knowledge on the symptoms and consequences of respiratory
muscle dysfunction in these patients. Therefore, this study
investigated the respiratory muscle strength in a group of stable
adolescent and adult CF patients. The aim of this study was to
assess respiratory muscle function and provide more clearness
about the consequences of possible respiratory muscle dysfunc-
tion in a representative sample of patients. The following
questions were a guideline during the study:
- Is dysfunction of the respiratory muscles present in a group
of stable adolescent and adult patients with CF?
- Are there gender-related differences in terms of respiratory
muscle strength?
- Is respiratory muscle strength related to exercise capacity, the
degree of post-exercise dyspnoea and leg discomfort, and/or
quality of life in patients with CF?
2. Subjects and methods
2.1. Patients
The study population consisted of 27 clinically stable
adolescent and adult CF patients (f/m: 14/13, age: 26±7 yr
(mean±SD)), recruited from the annual medical check-up for
CF patients in the Cystic Fibrosis Centre Utrecht. All patients
received a standard medical treatment, consisting of antibiotic-
and spray therapy, pancreatic enzymes- and vitamin supple-
ments. No patient used corticosteroids. CF patients who
underwent lung transplantation were excluded from this study.
All patients gave informed consent to the study, which was
approved by the hospital ethical committee. Some anthropo-
metric and lung function characteristics are shown in Table 1
(see Results).Table 1
Anthropometric and lung function characteristics of the included CF patients
Total group
(N=27)
Males
(N=13)
Mean±SD Range Mean±SD
Age, year 26±7 18–40 27±8
Height, cm 170±9 151–187 177±6
Weight, kg 61±11 36–88 65±9
BMI, kg/m2 21±3 16–29 21±3
FEV1, l 2±1 1–5 3±1
FEV1, % predicted 63±25 20–105 71±28
FEV1/FVC, % 65±13 46–89 66±14
IVC, l 4±1 1–6 5±1
IVC, % predicted 71±24 29–105 80±20
BMI: Body mass index; FEV1: Forced Expiration Volume in 1 s; FVC: Forced Vita
a t-test for unpaired samples.2.2. Study design
A cross-sectional design was used to obtain relevant data
during a study period of 3 months. To assess the functional
capacity of the patients a number of variables were measured
(see below).
2.3. Measurements
2.3.1. Body mass index
The body mass index (BMI) was used to assess weight
relative to height and was calculated by dividing body weight
(in kg) by height (in m) squared.
2.3.2. Respiratory muscle strength
Respiratory muscle strength was assessed by measuring max-
imal static expiratory mouth pressure (Pemax) starting from
total lung capacity (TLC) and maximal static inspiratory mouth
pressure (Pimax) starting from residual volume (RV). Pemax and
Pimax were determined using a Micro Mouth Pressure Meter
(MicroMedical, Rochester, UK). A conventional mouthpiece and
nose clip were used. Values were expressed in cmH2O. Patients
had to exhale, respectively, to inspire as forcefully as possible, and
with encouragement of the physical therapist the manoeuvre was
repeated about 4–8 times. The highest value maintained for 1 s
was taken for further analysis. Reference values of Wilson et al.
[9] were used for comparison.
2.3.3. Lung function
Forced Expiration Volume in 1 s (FEV1), Forced Vital
Capacity (FVC), their ratio (FEV1/FVC) and Inspiratory Vital
Capacity (IVC) were determined by spirometry (ZAN,
Oberthulba, Germany), or with a Microloop (Micro Medical,
Rochester, UK). Both devices were calibrated regularly. All
variables were expressed as a percentage of the predicted value
for healthy subjects, matched for age, body weight, height and
gender [10].
2.3.4. Peripheral muscle strength
Measures of peripheral muscle strength included isometric
quadriceps and hand-grip strength. The maximal isometricFemales
(N=14)
Difference between
males and females
Range Mean±SD Range p-value a
19–40 25±5 18–34 NS
165–187 163±7 151–176 b0.05
50–77 57±11 36–88 b0.05
18–26 21±3 16–29 NS
1–5 2±1 1–4 b0.05
29–102 55±22 20–105 NS
46–83 64±12 49–89 NS
2–6 3±1 1–4 b0.05
40–102 62±25 29–105 NS
l Capacity; IVC: Inspiratory Vital Capacity; NS: not significant.
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Cybex dynamometer (Lumex, Ronkonkoma, NY). The subject
was positioned with a hip angle of 90° and a knee joint angle of
60°, and stabilized with a trap around the waist, the upper leg
and the distal tibia. The best of three repetitions was referred to
as peak force development [11]. Maximal hand-grip strength
was assessed with a Jamar (TEC, Clifton, NJ) that enabled
standardized hand and grip position [12]. Both hands were
tested two times, and the peak value for each hand was used for
further analysis. Peak values were expressed as a percentage of
predicted values for healthy, age and gender matched subjects
[11,12].
2.3.5. Exercise capacity
The modified shuttle test (a field test with proven reliability,
repeatability and sensitivity in adult CF patients [13]) was used
to evaluate the symptom-limited exercise capacity in CF
patients. The test is a 15-level, externally paced test that
required patients to walk/run at increasing speeds back and
forth on a 10 m course. The test starts with a speed of 1.8 km/h
(level 1), followed by an increment of 0.6 km/h at each
successive level [13]. The test ends when patients become
unable to maintain the required speed, fail to complete a shuttle
in the time allowed, or attain the maximal distance of 1500 m.
During the test heart rate (Polar Electro OY, Finland) and
oxygen saturation at the fingertip (Oximetry sensor, Dolphin
Medical Inc, Hawthorne, CA) were measured. The tests were
supervised by physical therapists, with a physician immediately
available in the vicinity of the testing area. For further analysis
the total walk/run distance and oxygen saturation were used.
2.3.6. Feelings of post-exercise dyspnoea and leg discomfort
Immediately after the MST, patients were asked to rate
subjective feelings of dyspnoea and leg discomfort on an 11-
point Borg scale in response to the questions, “how breathless
do you feel?”, and, “how much leg discomfort do you feel?”,
respectively (score 0=no symptoms; score 10=maximal
symptoms) [14].
2.3.7. Quality of life
The disease-specific Cystic Fibrosis Questionnaire for
adolescents and adults (CFQ-14+) was used to assess the
quality of life (QOL) [15]. This questionnaire consists of 47
items, divided into 9 domains. The domains are physical
functioning, energy/well-being, emotions, social limitations,Table 2
Respiratory muscle strength of the included CF patients
Total group
(N=27)
Males
(N=13)
Mean±SD Range Mean±SD
Pimax, cmH20 113±30 58–160 131±22
Pemax, cmH20 129±43 61–246 153±42
Pimax, % predicted 124±32 82–226 115±19
Pemax, % predicted 107±32 66–172 100±31
Pimax: maximal inspiratory pressure; Pemax: maximal expiratory pressure; NS: not
a t-test for unpaired samples.role limitations, self-image, eating disturbances, treatment
burden, and embarrassment. The symptom scales concern
respiratory, digestive and body weight problems. The scores are
calculated by a standardized method, with higher scores
corresponding to higher QOL [15]. In addition, the Dutch
version of the Medical Research Council (MRC) dyspnoea
scale was used as a simple and valid method for categorizing
patients in terms of their disability due to lung diseases [16].
Patients answered 6 questions about dyspnoea in daily
activities. Score 0 indicates “I never experience breathlessness
in daily life”, and score 5, “I am too breathless to leave the
house”.
2.4. Statistical analysis
Data were analyzed using the Statistical Package for the
Social Sciences (SPSS, version 12.0, SPSS Inc, Chicago, IL).
The t-test for unpaired samples was used to compare the data of
the male and female CF patients with reference values when
data were normally distributed. For data with a skewed
distribution log transformation was used. For data which
remained non-normally distributed after log transformation,
the two sample Kolmogorov–Smirnov test was used. Correla-
tions among variables were calculated by Spearman's rank
correlation coefficient (rs). Statistical significance was accepted
at p≤0.05, and results are presented as means±SD, unless
otherwise stated.
3. Results
Anthropometric and lung function characteristics of the
patients are presented in Table 1. Male patients were higher and
heavier than females, and showed higher values of FEV1 and
IVC.
Table 2 shows the results of the respiratory muscle strength
and the comparison with the predicted reference values
expressed in %. Pimax of the total group was significantly
higher than reference values (p=0.00), whereas Pemax was not
different from these values (p=0.24). Pimax and Pemax in
female patients were significantly lower than in male patients.
However, expressed as a percentage of the predicted values,
these values were higher in female than in male patients,
although this difference was not statistically significant.
The results of peripheral muscle strength, exercise capacity,
oxygen saturation, feelings of post-exercise dyspnoea and legFemales
(N=14)
Difference between
males and females
Range Mean±SD Range p-value
86–160 96±26 58–156 b0.05 a
100–246 107±30 61–173 b0.05 a
82–152 133±39 90–226 NS
68–171 114±32 66–172 NS
significant.
Table 3
Peripheral muscle strength, exercise capacity, oxygen saturation, post-exercise feelings of dyspnoea and leg discomfort, and MRC dyspnoea scale of the included CF
patients
Total group
(N=27)
Males
(N=13)
Females
(N=14)
Difference between
males and females
Mean±SD Range Mean±SD Range Mean±SD Range p-value
HG left, kg 36±15 8–62 48±11 28–62 26±9 8–42 b0.05 a
HG right, kg 39±16 13–75 51±11 30–75 27±8 13–40 b0.05 a
HG left, % predicted 92±28 28–145 97±22 51–127 87±34 28–145 NS
HG right, % predicted 88±22 45–136 94±21 61–136 82±21 45–118 NS
QF, N 179±72 73–368 227±72 83–368 134±33 73–190 b0.05 a
QF, % predicted 60±24 22–131 72±27 22–131 48±11 30–75 b0.05 b
MST, m 1040±382 450–1500 1314±307 450–1500 786±247 460–1070 b0.05 b
SaO2, % 86±7 64–94 82±10 64–93 89±4 81–94 NS
HR, bpm 174±14 140–196 178±17 140–193 171±12 158–196 NS
Post-exercise dyspnoea feelings 7±2 4–10 6±2 4–8 7±2 5–10 NS
Post-exercise leg discomfort 6±2 2–10 6±2 3–9 6±2 5–10 NS
MRC dyspnoea scale 2±1 0–4 2±1 0–3 3±1 2–4 b0.05 b
QF: quadriceps force; MST: modified shuttle test; SaO2: oxygen saturation at the end of the MST; HR, bpm: heart rate in beats per minute at the end of the MST;
MRC: medical research council; NS: not significant.
a t-test for unpaired samples.
b Kolmogorov–Smirnov test.
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Table 3. Peripheral muscle strength, expressed in absolute
values was significantly lower in female than in male patients.
As percentage of predicted values quadriceps force was
significantly lower in female patients than in male patients.
Also the walk/run distance of the MSTwas less in females than
in males. In addition, the MRC score showed that female
patients experienced more dyspnoea in daily life than male
patients.
Table 4 shows the CFQ scores of the CF patients. The female
patients showed only significantly lower scores than male
patients for physical functioning and respiratory problems.
The relationship between respiratory muscle strength and
other variables showed for the total group a positive correlation
between Pimax and the total walk/run distance of the MST
(rs=0.59, p=0.001). Pimax was also significantly correlatedTable 4
Scores of the Cystic Fibrosis Questionnaire (CFQ-14+) for the included CF patients
Domains and symptom scales Total group
(N=27)
Males
(N=13)
Mean±SD Range Mean±SD
Physical functioning 74±22 17–100 82±23
Role limitations 80±18 42–100 84±18
Energy/well-being 62±17 17–92 69±16
Emotions 75±24 17–92 82±17
Social limitations 75±15 39–94 81±16
Self-image 87±19 33–100 85±19
Eating disturbances 89±16 44–100 93±15
Treatment burden 72±22 22–100 76±23
Embarrassment 58±21 11–89 63±22
Body weight problems 80±27 0–100 81±30
Respiratory problems 72±14 50–100 79±13
Digestive problems 83±16 33–100 84±10
NS: not significant.
a t-test for unpaired samples.
b Kolmogorov–Smirnov test.with social limitations of the CFQ-14+ (rs=0.63, p=0.001).
Pimax and Pemax were positively correlated with the peak
hand-grip and quadriceps forces. The correlations between Pimax
and peak hand-grip force left and right were rs=0.50 (p=0.008),
and rs=0.60 (p=0.001), respectively, and with peak quadriceps
force rs=0.56 (p=0.003). For Pemax the following correlations
were calculated: with peak hand-grip force left: rs=0.60
(p=0.001), with peak hand-grip force right: rs=0.60 (p=0.001),
and with peak quadriceps force: rs=0.53 (p=0.005). No
correlations were found between respiratory muscle strength and
the MRC scale scores or the category scores for dyspnoea.
The male patients showed significant correlations between
Pimax and lung function (with FEV1% pred: rs = 0.66,
(p=0.014), with FEV1/FVC: rs=0.65, (p=0.016), and with
IVC% pred.: rs =0.71, (p=0.007)). Pimax was also correlated
with different domains and symptom scales of the CFQ (socialFemales
(N=14)
Difference between
males and females
Range Mean±SD Range p-value
17–100 67±20 29–92 b0.05 b
50–100 77±18 42–100 NS
42–92 56±17 17–79 NS
40–100 69±28 0–100 NS
39–94 71±12 56–89 NS
33–100 88±19 44–100 NS
56–100 85±16 44–100 NS
22–100 69±21 33–100 NS
11–89 53±19 11–79 NS
0–100 80±25 33–100
56–100 67±13 50–89 b0.05 a
67–100 81±21 33–100 NS
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(rs≥0.61, p≤0.05)), and with the MRC dyspnoea scale
(rs =0.63, p≤0.05). In female patients the Pimax showed only
statistically significant correlations with the Borg scores of
dyspnoea and leg discomfort (rs=0.58, and 0.62, p≤0.05,
respectively). In contrast to the correlations calculated for the
total group, the male as well as the female patients showed no
correlations between respiratory and peripheral muscle
strength.
4. Discussion
We evaluated respiratory muscle strength in stable adoles-
cent and adult CF patients. The CF patients in the present study
showed a significantly higher Pimax compared to reference
values, whereas Pemax remained within the range of these
values. This suggests that an increased work of breathing as a
consequence of airway obstruction may have a conditioning
effect on respiratory muscles in CF patients. This result is in line
with the results of several other studies [1,4,17] that also
showed that severe respiratory muscle weakness was uncom-
mon in CF. No significantly increased respiratory muscle
strength was found in these studies, in spite of the comparable
degree of airway obstruction with the patients in the present
study [1,4]. Barry and Gallagher [1] found a negative relation-
ship between corticosteroid medication and respiratory muscle
strength. They concluded that corticosteroids have a negative
effect on respiratory muscle strength. In the present study, no
patients used corticosteroids during the time period that they
were tested, and this can be the reason that we observed an
increase in inspiratory muscle strength. In contrast, we observed
a decreased peripheral muscle strength in our patient group
(QF=60%, HG left=92%, and HG right=88% of the predicted
reference values). Previous studies with CF patients [1,4]
showed also decreased peripheral muscle strength. The patients
in the study of Mier et al. [4] had a mean QF of 68%, and the
patients in the study of Barry and Gallagher [1] had a mean QF
of about 46% and a HG of about 68% of the predicted reference
value. Therefore, in contrast to an increased respiratory muscle
strength in our group of CF patients, we observed a decreased
peripheral muscle strength, probably due to physical inactivity,
an intrinsic muscle defect, malnutrition or a combination of
these factors [3,18].
The results of the present study are in contrast to the studies of
Lands et al. [3] and Szeinsberg et al. [19], who found a reduced
Pimax and Pemax, despite the fact that the lung function of their
patients was comparable to the data of the present study. Both
studies [3,19] showed that malnutrition can result in decreased
respiratory muscle strength. The mean BMI values of the CF
patients in these studies (17.58 and 20.57 kg/m2, respectively)
were slightly lower than in the present study (21.2 kg/m2),
indicating that malnutrition was more important in their study
population than in our patients. Lands et al. [3] and Szeinberg et
al. [19] also found that the degree of hyperinflation was an
important determinant of a decreased inspiratory muscle
strength. Although the degree of hyperinflation was notmeasured in the present study, our results indicate that
hyperinflation in our patients was not a limiting factor.
This study focused also on gender-related differences in
respiratory muscle strength. No statistically significant
differences between male and female patients were found
when Pimax and Pemax were expressed as % of predicted
values, although these values were higher in female patients.
Concerning the lung function, the male patients had a
significantly better FEV1 and IVC, and as % of predicted,
these lung functions are clearly higher than in the female
patients. In addition, the peak quadriceps force (in absolute
values and expressed as % pred.), the peak hand-grip force (in
absolute values), the MRC dyspnoea scores, the CFQ domain
physical functioning, and the CFQ symptom respiratory
problems were significantly higher in male patients than in
female patients. Therefore, female CF patients were in a more
severe state of the disease, due to a decreased lung function
and lower MRC- and CFQ scores. We suggest that as
compensation the respiratory muscle strength will be rela-
tively higher in the group of female CF patients. This is in
agreement with observations in previous studies in CF patients
[4,17], in which no respiratory muscle weakness was found.
Another focus was the relationship between respiratory
muscle strength and exercise capacity, degree of dyspnoea and
leg discomfort, and quality of life. A positive correlation was
found between inspiratory muscle strength and the walk/run
distance of the MST. This suggests that a training-related
inspiratory muscle strength can play a positive role in the
limited exercise capacity of CF patients. It is conceivable that a
better inspiratory muscle strength will compensate the negative
effects of a reduced lung function on the walk/run performance.
A positive correlation was also found between Pimax and the
Borg scores of leg discomfort. This is in line with a study of
Enright et al. [20], who showed a positive effect on exercise
capacity after a high-intensive training of respiratory muscles.
In contrast to our expectations, we could not calculate a
significant correlation between Pimax and SaO2% during
exercise. Moreover, there was no significant gender-related
difference in SaO2% during exercise (see Table 3). We are not
able to compare these results with those of other studies,
because studies that are focused on these correlations in CF
patients are lacking. The present study found no significant
correlations between respiratory muscle strength and the MRC
dyspnoea scale or the Borg scores of dyspnoea. This is
consistent with results of a study of De Jong et al. [6], who
found no changes in the degree of dyspnoea in CF patients after
respiratory muscle training. Our study showed also a positive
correlation between Pimax and social limitations, indicating
that a higher Pimax was associated with a lower score on social
limitations. This observation is in contrast to the results of a
previous study with CF patients [20], probably due to the use of
different questionnaires on QOL. Our study used a question-
naire specifically developed for CF patients, while Enright et al.
[20] used a questionnaire that was validated for patients with
chronic obstructive lung diseases.
Before drawing conclusions from this study, some limita-
tions must be acknowledged. A potential limitation could be the
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included. Thus, our findings cannot be generalized to CF
patients, who are not clinically stable. Another limitation may
be that the small study population was characterized by a
heterogeneity of physical characteristics. For future studies we
recommend to include patients based on their degree of airway
obstructions, because this study suggests that the presence of
airway obstruction may have a conditioning effect on
respiratory muscles. Such a study design may contribute to
more knowledge about the relationship between respiratory
muscle strength and the severity of airway obstruction.
In conclusion, this study showed an increased Pimax in
stable adolescent and adult CF patients. Compared to male
patients, the more severe CF disease in female patients leads to
higher predicted Pimax and Pemax values, although this
difference was not statistically significant. These results suggest
that increased work of breathing will have a conditioning effect
on respiratory muscles. The positive correlation between
respiratory muscle strength and exercise capacity indicates
that training-related inspiratory muscle strength can play a
positive role in the limited exercise capacity of CF patients.
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